Calcium Kinetics in Children with Osteogenesis Imperfecta Type III and IV: Pre- and Post-Growth Hormone Therapy

Children with osteogenesis imperfecta (OI) type III and type IV were studied using a ⁴²Ca stable isotope technique. Serum dilution kinetics of ⁴²Ca were studied pre- and post-growth hormone (GH) treatment in 9 OI III (age range 5–9 years) and 8 OI IV patients (age range 5–12 years). Each subject was studied twice: at baseline and following GH therapy (range 1–1.5 years). Isotopic enrichments of ⁴²Ca were followed over 7 days using thermal ionization mass spectrometry. A binding site model, which describes reversible and irreversible binding of calcium (Ca) ions to postulated short- and long-term binding sites in bone, was used to analyze the kinetic data. In type III patients, GH treatment (1) increased the fraction of short-term binding sites, θ (0.777 ± 0.112 versus 0.877 ± 0.05, respectively; P= 0.034); (2) increased the apparent half-life of a Ca ion attached to the long-term binding site by 76% (P= 0.009); (3) although not statistically significant (P= 0.098), a trend toward an increased growth rate was observed with increasing change in θ (Δθ); (4) patients experienced a 75% increase in growth rate during the first 6 months of treatment. In type IV patients, GH treatment increased the apparent half-life of a Ca ion attached to the long-term binding site by 83% (P= 0.048), however, no trend toward an increased growth rate was observed with increasing Δθ in these patients. These significant changes in Ca binding to bone may influence growth in type III patients. Received: 10 September 1999 / Accepted: 29 February 2000     

针刺治疗稳定性心绞痛30例体会

目的:比较针刺与药物治疗稳定性心绞痛的疗效差异。方法:随机选取稳定性心绞痛患者,分为针刺组30例、药物组2 2例,分别比较治疗后两组症状、心电图及硝酸甘油停减情况。结果:症状疗效方面:针刺组有效率为90 .0 0 %,药物组有效率为81 .82 %,两组比较有显著性差异(P <0 .0 5 )。心电图改善情况两组未见明显差异。硝酸甘油停减情况:针刺组停药率为2 3.3%,药物组停药率为1 8.2 %,两组比较无明显差异。结论:针刺具有明显改善稳定性心绞痛症状的功效。     

The role of polysaccharide peptide of Ganoderma lucidum as a potent antioxidant against atherosclerosis in high risk and stable angina patients

ObjectivesAntioxidants can reduce oxidative radicals that affect the early phase of atherogenesis, that is endothelial dysfunction. Polysaccharide Peptide (PsP) derived from Ganoderma lucidum has an active substance in the form of β-glucan. Previous studies have proven the PsP of Ganoderma lucidum as an effective antioxidant in atherosclerotic rats and shows no toxicity in animal model. This study aims to prove the effect of PsP as potent antioxidant in high risk and stable angina patients.MethodThis is a clinical trial conducted to 37 high risk and 34 stable angina patients, which were determined based on ESC Stable CAD Guidelines and Framingham risk score, with pre and post test design without control group. The parameters are superoxide dimustase (SOD) and malondialdehyde (MDA) concentration, circulating endothelial cell (CEC) and endothelial progenitor cell (EPC) counts. The patients were given PsP 750 mg/day in 3 divided dose for 90 days. Paired t-test was performed for normally distributed data, and Wilcoxon test for not normally distributed data, and significant level of p ≤ 0,05.ResultsSOD level in high risk patients slightly increased but not statistically significant with p = 0,22. Level of SOD in stable angina group significantly increased with p = 0,001. MDA concentration significantly reduced in high risk and stable angina patients with p = 0.000. CEC significantly reduced both in high risk and stable angina patients, with p = 0.000 in both groups. EPC count significantly reduced in high risk and stable angina with p = 0.000.ConclusionPsP of Ganoderma lucidum is a potent antioxidant against pathogenesis of atherosclerosis in stable angina and high risk patients     

慢性阻塞性肺病患者稳定期肺弥散功能检测意义

目的：探讨稳定期慢性阻塞性肺病患者肺弥散功能检测意义。方法选择稳定期慢性阻塞性肺病患者患者100例为研究组，另选择健康志愿者30例为对照组。分别检测两组肺通气功能检查，CO弥散测定，肺泡毛细血管膜弥散能力，肺泡毛细血管血容量等。结果中度组到极重度组DLCO、Dm、Vc占预计值百分比与对照组比较显著下降（P＜0.01）。并且随着病情的加重，下降也逐渐显著。DLCO与Dm的相关系数为0.899，与Vc的相关系数为0.874，P均＜0.01，Dm与Vc的相关系数为0.821，P＜0.01。DLCO、Dm、Vc与疾病的严重程度呈显著线性相关性（P＜0.01）。结论慢性阻塞性肺疾病患者稳定期肺弥散功能障碍随着疾病严重程度的发展而加重。     

NRAGE影响人食管癌细胞放射抗性的作用及其机制研究

背景与目的：食管癌是全球威胁人类生命和健康的常见恶性肿瘤之一，中国每年食管癌发病人数占全球发病总人数的一半以上，以食管鳞癌最为常见。放疗是食管癌三大治疗手段之一，而放射抗性是导致其治疗失败的主要原因。神经营养因子受体相互作用MAGE类药物（neurotrophin receptor-interacting MAGE homolog，NRAGE）在放射抗性细胞株TE13R120中表达量明显高于亲本TE13细胞，且NRAGE亚细胞定位变化可能参与食管癌细胞放射抗性的形成。通过基因转染构建NRAGE稳定表达的食管癌细胞系，以进一步明确NRAGE基因与食管鳞癌细胞放射抗性的关系，分析该基因影响放射抗性的具体机制。方法：通过基因转染构建NRAGE稳定表达的食管癌细胞系。采用细胞克隆形成实验检测细胞放射敏感性，采用流式细胞术检测细胞周期及凋亡；细胞划痕、Transwell侵袭实验检测细胞迁移、侵袭能力，采用实时荧光定量聚合酶链反应（real-time fluorescence quantitive polymerase chain reaction，RTFQ-PCR）和蛋白质印迹法（Western blot）检测细胞中β-catenin表达情况。组间差异采用t检验或方差分析。结果：实验分为转染过表达组（Eca109/NRAGE组）和空白对照组（Eca109组）。Eca109/NRAGE细胞中NRAGE的表达量明显高于Eca109（t=29.65，P<0.05）。照射后Eca109/NRAGE细胞的放射抗性显著高于Eca109。流式细胞术检测结果显示，Eca109/NRAGE细胞中对射线抵抗性最强的S期细胞比例增加，对射线最敏感的G ₂ /M期减少。Eca109/NRAGE细胞凋亡率较Eca109细胞降低（t=3.268，P<0.05）。Eca109/NRAGE细胞迁移和侵袭能力均高于Eca109。RTFQ-PCR和Western blot检测结果显示，β-catenin的mRNA表达及蛋白水平在Eca109/NRAGE细胞中明显高于Eca109（t=15.87，P<0.05）。结论：NRAGE参与Eca109细胞放射抗性的形成，改变细胞的细胞周期分布和凋亡情况，影响细胞迁移及侵袭能力并可能影响食管癌细胞的放射敏感性，该作用可能与激活Wnt/β-catenin信号转导通路有关。     

健康指导在稳定期COPD治疗中的作用观察

目的探究健康指导在稳定期COPD治疗中的作用。方法随机选取2010年10月至2013年10月我科收治的126例COPD患者,所取病例分为对照组(63例)、指导组(63例)。对照组予以常规治疗,指导组予以健康指导加常规治疗,对照分析两组患者的治疗效果。结果对照组急性加重频次和并发症的发生率明显高于指导组。结论在稳定期COPD的治疗中予以积极健康指导,可减轻患者症状,减少患者的住院率及并发症发生,延缓肺功能的下降,提高了生活质量,     

曲美他嗪与硝酸异山梨酯治疗稳定性劳力型心绞痛效果比较

目的：探析曲美他嗪与硝酸异山梨酯治疗稳定性劳力型心绞痛效果。方法整群选取该院2012年1月-2014年11月收治的78例稳定性劳力型心绞痛患者,对其临床资料进行回顾性分析,并在患者及家属知情同意的情况下将其分为治疗组和对照组,治疗组给予曲美他嗪,对照组给予硝酸异山梨酯,对比分析两组患者的治疗有效率及患者恢复情况。结果经治疗后,治疗组患者的有效率为97.46%,对照组患者的有效率为84.62%,两者相比较差异显著,P<0.05有统计学意义;两组患者的各项临床指标均有所改善,且治疗组显著优于对照组,P<0.05有统计学意义;治疗组患者的不良反应发生率为7.69%,对照组不良反应反生率为17.95%,两组比较差异有统计学意义(P<0.05)。结论曲美他嗪与硝酸异山梨酯治疗稳定性劳力型心绞痛都有较好的效果,但曲美他嗪能够更好的改善患者心肌缺血的症状,且患者耐受性好,值得应用。     

中医肺康复法治疗慢性阻塞性肺疾病稳定期患者的疗效分析

目的：探讨与分析中医肺康复法治疗慢性阻塞性肺疾病稳定期患者的临床效果。方法将2010年9月~2013年9月于我院接受治疗的100例慢性阻塞性肺疾病稳定期患者作为研究对象,按照入院顺序随机将其分为对照组与观察组各50例,对对照组患者选用口服多索茶碱片治疗,对观察组则给予中医肺康复法治疗,对比观察两组患者的治疗效果。结果观察组患者在接受治疗后,中医症候评分显著低于对照组患者,且治疗后其生存质量的评分提高情况明显高于对照组患者,<0.05。结论选用中医肺康复法能够显著提高COPD稳定期患者的治疗效果,改善其肺部组织功能,延长其生存时间,并提高患者的生活质量。